Jo-1-Ab ELISA
- Regulatory Status
- EU: CE
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 3 x 30 min
- Standard range
- 0 - 100 U/mL, cut-off 4 U/mL
- Specimen / Volumes
- 10 µL serum, plasma
- Substrate / isotope
- TMB 450 nm
Enzyme immunoassay for the qualitative and quantitative determination of IgG antibodies against Jo-1 in human serum or plasma (EDTA, citrate or heparin).
Polymyositis (PM) and dermatomyositis (DM) are inflammatory, autoimmune mediated disorders of the connective tissue with unknown etiology (1). They primarily damage skin and/or muscles, but may also affect other organs as e. g. the lung. Without treatment (standard therapy is immune suppression), they tend to develop into a life threatening state(2). Since immunosuppressive agents are known to cause considerable side effects, early diagnosis of PM/DM is essential, in order to keep their dosage as low as possible.
A striking feature of PM/DM is the occurrence of antibodies to aminoacyl-tRNA synthetases; functionally related but immunologically distinct enzymes(3,4,5). About 30 % of all myositis patients carry antibodies against histidyl-tRNA synthetase (EC 6.1.1.21), a 100 kDa dimeric antigen, located in the cytoplasma and known as Jo-1 (derived from a patient’s name) (6). Jo-1 Ab positive sera represent about 75 % of all sera with anti-synthetase autoantibodies (7). With few exceptions, these antibodies tend to be mutually exclusive. (6,8)
The term Jo-1 (or anti-synthetase) syndrome comprises the symptoms of interstitial pulmonary disease with fibrosing alveolitis. For these symptoms, Jo-1 antibodies possess a high predictive value (80 %). In most cases, this condition is clinically significant and may fatally end in adult respiratory distress syndrome (ARDS).(7,9,10)
The present enzyme-linked immuno sorbent assay (ELISA) is intended for the quantitative or qualitative determination of IgG antibodies directed against Jo-1 in human serum or plasma. The antigen used is a highly purified preparation of human histidyl-tRNA synthetase, expressed by baculovirus infected insect cells. The test is fast (incubation time 30 - 30 - 30 minutes) and flexible (divisible solid phase, readyto-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control check the assay performance.
For concrete data please consult the Instruction for Use in the download box on the top right side.
- Callen, J. P.: Dermatomyositis: diagnosis, evaluation and management. Minerva Medica 93-3 (2002), 157 - 167
- Ghate, J., et al.: A therapeutic update on dermatomyositis/polymyositis. Int J Dermatol 39 (2000), 81 - 87
- Mathews, M. B., Bernstein, R. M.: Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 304 (1983), 177 - 179
- Miller, F. W., et al.: Origin and regulation of a disease-specific antibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest 85 (1990), 468 - 475
- Miller, F. W., et al.: The role of an autoantigen, histidyl-transfer RNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA 87 (1990), 9933 - 9937
- Messinger, M.: Autoantikörper bei systemischen entzündlich-rheumatischen Erkrankungen (Kollagenosen). In: L. Thomas (ed.): Labor und Diagnose (2005), TH-Books-Verlags-Gesellschaft, Frankfurt/Main, 1139 - 1161
- Thomas, L.: Autoantikörper bei Muskelerkrankungen. In: L. Thomas (ed.): Labor und Diagnose (2005), TH-Books-Verlags-Gesellschaft, Frankfurt/Main, 1161 - 1168
- Targoff, I. N.: Myositis antibodies: aminoacyl-tRNA synthetase, signal recognition particle, Mi-2, and PMScl autoantibodies. In: Shoenfield, Y., et al. (eds.): Autoantibodies (2007), Elsevier Science, Amsterdam, 577 - 589
- Bernstein, R. M., et al.: Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J 289 (1984), 151 - 152
- Sommer, R., Eitelberger, F.: Wertigkeit der Gliadin-Antikörper im Serum zur Diagnose der Zöliakie. Wien Klin Wochenschr 104/4 (1992), 86 - 92
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.